# Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

> **NCT07465276** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 32 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Ficerafusp alfa
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07465276
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2028-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465276, "Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07465276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*